News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Sponsor & Foundation News

Kyowa Kirin Announces FDA Reviewing New Drug Application for Istradefylline

Acorda Therapeutics announces Inbrija Approved in US to Treat Off Periods in Parkinson’s Patients on Carbidopa/Levodopa

“Milestone Moment” as LRRK2 inhibitor enters human testing

The Parkinson Alliance Presented Patient-Centered Research on Vision and Parkinson’s Disease at American Congress of Rehabilitation Medicine in Dallas, Texas

Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia

Parkinson's Foundation Designates Three Centers of Excellence in Parkinson's Care

Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277)

Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day

Medtronic Launches New Clinician Programmer for Deep Brain Stimulation Therapy

Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)

Acorda Announces EMA Validation of the MAA Submission for INBRIJA™

Introducing Little Big Things™ from Sunovion Pharmaceuticals Inc.

Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting

Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film for the Treatment of OFF Episodes Associated with PD

Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

Lundbeck to acquire Prexton Therapeutics

Acorda Launches New Initiative - “Live Well. Do Tell.™” to Support People with Parkinson’s

Nuplazid and Clozaril Are Most Reliable Parkinson’s Psychosis Therapies, Review Finds

Acorda Announces FDA Acceptance of New Drug Application for INBRIJA™

Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis from EASE LID 2 Open-label Study

Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder) (December 21, 2018)

back to top

back to top

back to top